Human Chymase/CMA1 Antibody Summary
Accession # P23946
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human Chymase/CMA1 by Western Blot. Western blot shows lysates of human small intestine tissue. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human Chymase/CMA1 Monoclonal Antibody (Catalog # MAB4099) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for Chymase/CMA1 at approximately 28 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Human Chymase/CMA1 ELISA Standard Curve. Recombinant Human Chymase/CMA1 protein was serially diluted 2-fold and captured by Mouse Anti-Human Chymase/CMA1 Monoclonal Antibody (MAB40991) coated on a Clear Polystyrene Microplate (DY990). Mouse Anti-Human Chymase/CMA1 Monoclonal Antibody (Catalog # MAB4099) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (DY998) followed by Substrate Solution (DY999) and stopping the enzymatic reaction with Stop Solution (DY994).
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Chymases are a group of chymotrypsin-like serine proteases secreted by mast cells (1). They are synthesized as inactive precursors containing a 2‑residue propeptide, which needs to be removed by dipeptidyl peptidase I/cathepsin C for the enzymatic activity (2). Human Chymase encoded by the CMA1 gene is known to be involved in hypertention and heart failure through its ability to convert angiotensin I (Ang I) to angiotensin II (Ang II), which plays a key role in the regulation of arterial pressure (3). In addition, it is also important in physiological and pathological conditions including inflammation, fibrosis and processing of cytokines (4). Therefore, designing a specific inhibitor for Chymase activity has been a pharmacologic strategy to develop therapeutic agents.
- Caughey, G.H. (2004) in Handbook of Proteolytic Enzymes. Barrett, A.J. et al. ed. p. 1531, Academic Press, San Diego.
- Murakami, M. et al. (1995) J. Biol. Chem. 270:2218.
- Miyazaki, M. and S. Takai (2006) J. Pharmacol. Sci. 100:391.
- Nakajima, M. and N. Naya (2002) Jpn. J. Pharmacol. 90:206.
Citation for Human Chymase/CMA1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Chymase uptake by cardiomyocytes results in myosin degradation in cardiac volume overload
Authors: PC Powell, CC Wei, L Fu, B Pat, WE Bradley, JF Collawn, LJ Dell'Itali
Species: Human, Rat
Sample Types: Tissue Homogenates
Applications: Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human Chymase/CMA1 Antibody
There are currently no reviews for this product. Be the first to review Human Chymase/CMA1 Antibody and earn rewards!
Have you used Human Chymase/CMA1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image